KR20100094453A - 겔로부터 콤스타틴 유사체의 지속적 운반 - Google Patents

겔로부터 콤스타틴 유사체의 지속적 운반 Download PDF

Info

Publication number
KR20100094453A
KR20100094453A KR1020107008703A KR20107008703A KR20100094453A KR 20100094453 A KR20100094453 A KR 20100094453A KR 1020107008703 A KR1020107008703 A KR 1020107008703A KR 20107008703 A KR20107008703 A KR 20107008703A KR 20100094453 A KR20100094453 A KR 20100094453A
Authority
KR
South Korea
Prior art keywords
comstatin
analog
liquid composition
composition
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020107008703A
Other languages
English (en)
Korean (ko)
Inventor
세드릭 프랑수와
파스칼 데스차텔레츠
폴 올슨
Original Assignee
포텐시아 팔마큐티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 포텐시아 팔마큐티칼스, 인크. filed Critical 포텐시아 팔마큐티칼스, 인크.
Publication of KR20100094453A publication Critical patent/KR20100094453A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
KR1020107008703A 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반 Ceased KR20100094453A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US60/976,919 2007-10-02
US2646008P 2008-02-05 2008-02-05
US61/026,460 2008-02-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157016589A Division KR20150080007A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Publications (1)

Publication Number Publication Date
KR20100094453A true KR20100094453A (ko) 2010-08-26

Family

ID=40526950

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107008703A Ceased KR20100094453A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반
KR1020157016589A Ceased KR20150080007A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157016589A Ceased KR20150080007A (ko) 2007-10-02 2008-10-02 겔로부터 콤스타틴 유사체의 지속적 운반

Country Status (12)

Country Link
US (1) US20110182877A1 (enExample)
EP (1) EP2207530A4 (enExample)
JP (1) JP2010540654A (enExample)
KR (2) KR20100094453A (enExample)
CN (1) CN101854916A (enExample)
AU (1) AU2008308657A1 (enExample)
BR (1) BRPI0817524A2 (enExample)
CA (1) CA2701470A1 (enExample)
MX (1) MX2010003630A (enExample)
RU (1) RU2505311C2 (enExample)
WO (1) WO2009046198A2 (enExample)
ZA (1) ZA201002365B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
WO2009121065A2 (en) * 2008-03-28 2009-10-01 Apellis Ag Modulation and repletion/enhancement of the complement system for treatment of trauma
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
NZ607103A (en) 2010-09-03 2015-09-25 Santen Sas A water-in-oil type emulsion for treating a disease of the eye
ES2426603T3 (es) 2010-09-03 2013-10-24 Novagali Pharma S.A. Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
JP6522337B2 (ja) 2011-05-11 2019-05-29 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 細胞反応性、長時間作用型または標的化コンプスタチン類似体およびその使用
EP3524258B1 (en) * 2011-06-22 2025-10-01 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
US20160067357A1 (en) * 2012-08-17 2016-03-10 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
PT2920201T (pt) 2012-11-15 2020-04-03 Apellis Pharmaceuticals Inc Análogos de compstatina de longa ação e composições e métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
PL3154561T3 (pl) 2014-06-12 2019-12-31 Ra Pharmaceuticals, Inc. Modulowanie aktywności dopełniacza
US20180228811A1 (en) * 2014-12-12 2018-08-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
HRP20211824T1 (hr) 2015-01-28 2022-03-04 Ra Pharmaceuticals, Inc. Modulatori aktivnosti komplementa
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
MX392574B (es) * 2015-10-07 2025-03-24 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada para usarse en el tratamiento de trastornos oculares
RS60134B1 (sr) 2015-12-16 2020-05-29 Ra Pharmaceuticals Inc Modulatori aktivnosti komplementa
BR112019011053A2 (pt) 2016-12-07 2019-10-15 Ra Pharmaceuticals Inc moduladores da atividade do complemento
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
MA51162A (fr) * 2017-12-15 2020-10-21 Apellis Pharmaceuticals Inc Schémas posologiques et compositions et procédés associés

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
ES2373649T3 (es) * 2002-09-20 2012-02-07 The Trustees Of The University Of Pennsylvania Análogos de compstatina con actividad mejorada.
CN105582523B (zh) * 2005-10-08 2022-04-15 阿佩利斯制药公司 用于眼部病症的补体抑制素和其类似物
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
DK1960422T3 (da) * 2005-11-28 2012-08-13 Univ Pennsylvania Meget virksomme compstatin-analoger
EP1963529A2 (en) * 2005-12-22 2008-09-03 Alcon Research, Ltd. C3-convertase inhibitors for the prevention and treatment of age-related macular degeneration in patients with at risk variants of complement factor h
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
DK2148691T3 (en) * 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system

Also Published As

Publication number Publication date
US20110182877A1 (en) 2011-07-28
CN101854916A (zh) 2010-10-06
JP2010540654A (ja) 2010-12-24
WO2009046198A2 (en) 2009-04-09
AU2008308657A1 (en) 2009-04-09
KR20150080007A (ko) 2015-07-08
WO2009046198A3 (en) 2009-07-16
MX2010003630A (es) 2010-04-21
RU2010113513A (ru) 2011-11-10
EP2207530A4 (en) 2013-09-11
CA2701470A1 (en) 2009-04-09
RU2505311C2 (ru) 2014-01-27
EP2207530A2 (en) 2010-07-21
ZA201002365B (en) 2010-12-29
BRPI0817524A2 (pt) 2017-05-02

Similar Documents

Publication Publication Date Title
KR20100094453A (ko) 겔로부터 콤스타틴 유사체의 지속적 운반
CN101325963B (zh) 用于眼部病症的补体抑制素和其类似物
US10407466B2 (en) Methods of selecting compstatin mimetics
WO2022061304A1 (en) Methods of treating eye disorders
MX2008004656A (es) Compstatina y analogos de la misma para tratar trastornos oculares
HK1121380A (en) Compstatin and analogs thereof for eye disorders
HK1121380B (en) Compstatin and analogs thereof for eye disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20100421

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20131001

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20141223

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20150622

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20151008

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20141223

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I